BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2020 8:47:31 AM | Browse: 525 | Download: 739
 |
Received |
|
2020-05-12 02:21 |
|
Peer-Review Started |
|
2020-05-12 02:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-21 05:20 |
|
Revised |
|
2020-06-02 10:23 |
|
Second Decision |
|
2020-07-29 10:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-07-30 04:50 |
|
Articles in Press |
|
2020-07-30 04:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-03 22:47 |
|
Typeset the Manuscript |
|
2020-08-25 06:48 |
|
Publish the Manuscript Online |
|
2020-09-04 08:47 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu-Sen Zhai, Hui Yu, Tian-Tian Gu, Yan-Xia Li, Yan Lei, Hai-Yan Zhang, Tong-Huan Zhen and Yun-Ge Gao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yun-Ge Gao, MD, PhD, Chief Doctor, Oncology Section, PLA Strategic Support Force Characteristic Medical Center, No. 9 Anxiang North Lane, Chaoyang District, Beijing 100101, China. gaoyunge306dr@163.com |
| Key Words |
Icotinib hydrochloride; Epidermal growth factor receptor L858R/V834L; Non-small cell lung cancer; Stable disease; Case report; |
| Core Tip |
In non-small cell lung cancer, Epidermal growth factor receptor L858R/V834L compound mutation is rare and targeted treatment of this mutation with icotinib has not been reported. The patient failed to achieve complete or partial response, but achieved stable disease. The patient has been in remission for 1 year with no evidence of metastatic nodal disease, and there are signs of continuous remission. So far, the effect of this compound mutation on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors is not clear. It is also unclear which epidermal growth factor receptor tyrosine kinase inhibitor is most effective for this variation. This case suggests possible clinical treatment. |
| Publish Date |
2020-09-04 08:47 |
| Citation |
Zhai SS, Yu H, Gu TT, Li YX, Lei Y, Zhang HY, Zhen TH, Gao YG. Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report. World J Clin Cases 2020; 8(17): 3841-3846 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i17/3841.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i17.3841 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
